Roivant Sciences Ltd (ROIV) reported better-than-expected financial results for the second quarter of fiscal 2026. The company's earnings per share (EPS) came in at $-0.17, surpassing Wall Street's consensus estimate of $-0.34 by a notable $0.17. Revenue remained unchanged at $0.0 billion, aligning with analysts' expectations.
This update provides insight into Roivant's operational performance and financial health. The company engages in the biopharmaceutical sector, focusing on developing transformative medicines. Its pipeline includes brepocitinib, a small molecule inhibitor of TYK2 and JAK1, as well as fully human monoclonal antibodies like IMVT-1402 and batoclimab, which target IgG-mediated autoimmune indications. Additionally, Roivant is advancing mosliciguat, an inhaled sGC activator for pulmonary hypertension associated with interstitial lung disease.
The company will host its earnings conference call at BMO to discuss these results further and provide additional commentary on its business performance. Investors are encouraged to review the full earnings release and listen to management's insights for a comprehensive understanding of the quarter's performance and future outlook.
As of November 8, 2025, Roivant Sciences Ltd boasts a market capitalization of $14.1 billion, with a trailing twelve-month EPS of $-0.70. The next earnings report is scheduled for November 9, 2025, with an EPS estimate of $-0.34 and revenue expectations of $7.1 million.